This ASX biotech stock is tipped to double or even triple in value

Investors in ASX biotech stock Clinuvel Pharmaceuticals Ltd (ASX: CUV) have endured a frustrating few years.

The ASX biotech stock was down 1.3% to $10.28 during Thursday afternoon trading. While shares have climbed 15% over the past month, they remain down 17% in 2026, have slipped…